Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531255 · ClinicalTrials.gov registry record · Phase 3
Pegcetacoplan Long Term Safety and Efficacy Extension Study
A Phase 3 study of PNH, sponsored by Apellis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT03531255 is a Phase 3 study of PNH that is active but no longer recruiting, run by Apellis Pharmaceuticals. The registered enrollment target is 160 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT03531255, a Phase 3 study of PNH, is active but no longer recruiting, sponsored by Apellis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
Conditions Studied
Interventions
- DRUG Pegcetacoplan
Study Locations (20)
Other
- Cliniques Universitaires Saint-luc - Brussels
- AZ Delta - Roeselare
- Acibadem City Clinic Tokuda Hospital - Sofia
- National Specialized Hospital for Active Treatment of Haematologic Diseases - Sofia
- Hospital Center Chalon Sur Saone William Morey - Chalon-sur-Saône
- CHRU de Lille - Lille
Florida
- Cancer Specialists of North Florida - Jacksonville
- Lakes Research - Miami
Alberta
- University of Calgary - Calgary
- Alberta Health Services - Edmonton
California
- University of Southern California - Los Angeles
Colorado
- Denver Health Medical Center - Denver
Illinois
- Northwestern University - Chicago
Indiana
- Investigative Clinical Research of Indiana - Indianapolis
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2025-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03531255
The ClinicalTrials.gov registry entry for NCT03531255 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PNH appearing as the primary indexed condition, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT03531255 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Florida, Alberta.
Frequently Asked Questions
What is clinical trial NCT03531255 about?
NCT03531255 is a clinical study titled "Pegcetacoplan Long Term Safety and Efficacy Extension Study". This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
What is the current status of trial NCT03531255?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2018-08-27. Estimated completion is 2025-06.
What conditions does trial NCT03531255 study?
This clinical trial studies the following conditions: PNH.
What interventions are being tested in trial NCT03531255?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT03531255?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03531255 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PNH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.